Fibrinolytics and AntifibrinolyticsFedor Bachmann Springer Science & Business Media, 25 ene 2001 - 599 páginas This book covers basic aspects of the molecular biology, biochemistry and pharmacology of the plasminogen-plasmin (fibrinolytic) system. Individual chapters, written by well-known experts in the field, are devoted to plasminogen and its activation, the tissue-type plasminogen activator (tPA), the urinary-type-plasminogen activator (uPA), inhibitors of the fibrinolytic system, and the assembly of fibrinolytic constituents on cell surfaces. The major part of the book deals with the therapeutic use of thrombolytic agents in myocardial infarction, deep venous thrombosis, pulmonary embolism, peripheral arterial occlusions and stroke. The newest thrombolytic agents are discussed in depth. Results of major clinical trials up to the end of 1999 are critically evaluated. The volume is a modern up-to-date presentation of the entire field of the treatment of arterial and venous thromboses with thrombolytic agents. |
Índice
II | 3 |
IV | 5 |
V | 7 |
VI | 10 |
VII | 13 |
VIII | 25 |
X | 28 |
XI | 29 |
LXXX | 350 |
LXXXI | 352 |
LXXXII | 353 |
LXXXIII | 354 |
LXXXIV | 356 |
LXXXV | 357 |
LXXXVI | 358 |
LXXXVIII | 363 |
XII | 43 |
XIII | 57 |
XV | 58 |
XVI | 59 |
XVII | 60 |
XVIII | 70 |
XIX | 72 |
XX | 91 |
XXI | 92 |
XXII | 93 |
XXIV | 94 |
XXV | 100 |
XXVI | 111 |
XXIX | 114 |
XXX | 119 |
XXXI | 121 |
XXXII | 122 |
XXXIII | 123 |
XXXIV | 124 |
XXXV | 126 |
XXXVI | 141 |
XXXVIII | 142 |
XXXIX | 148 |
XL | 150 |
XLI | 155 |
XLII | 171 |
XLIII | 173 |
XLV | 177 |
XLVI | 209 |
XLVIII | 212 |
XLIX | 216 |
L | 231 |
LII | 232 |
LIV | 238 |
LV | 239 |
LVI | 249 |
LVII | 250 |
LVIII | 261 |
LXI | 268 |
LXII | 287 |
LXV | 289 |
LXVI | 296 |
LXVII | 309 |
LXVIII | 323 |
LXIX | 325 |
LXXI | 327 |
LXXII | 328 |
LXXIII | 334 |
LXXIV | 336 |
LXXV | 341 |
LXXVI | 343 |
LXXVII | 349 |
XC | 364 |
XCI | 366 |
XCII | 367 |
XCIII | 368 |
XCIV | 373 |
XCV | 378 |
XCVII | 379 |
XCVIII | 381 |
XCIX | 387 |
CI | 388 |
CII | 392 |
CIII | 410 |
CIV | 411 |
CV | 423 |
CVI | 425 |
CVII | 426 |
CVIII | 429 |
CIX | 432 |
CX | 435 |
CXI | 437 |
CXII | 439 |
CXIII | 441 |
CXIV | 442 |
CXV | 443 |
CXVI | 451 |
CXVIII | 453 |
CXX | 459 |
CXXI | 464 |
CXXII | 466 |
CXXIV | 467 |
CXXVI | 473 |
CXXVIII | 474 |
CXXIX | 475 |
CXXX | 479 |
CXXXI | 481 |
CXXXII | 484 |
CXXXIII | 486 |
CXXXIV | 487 |
CXXXV | 493 |
CXXXVII | 494 |
CXXXVIII | 510 |
CXXXIX | 512 |
CXLI | 521 |
CXLIII | 524 |
CXLIV | 531 |
CXLV | 543 |
CXLVI | 557 |
CXLVII | 559 |
CL | 567 |
CLI | 575 |
Otras ediciones - Ver todo
Términos y frases comunes
acti acute myocardial infarction alteplase amino acids angiographic anistreplase antibody antigen aprotinin aspirin Biochem Biol Chem bleeding blood bolus Califf RM Circulation clearance clinical clot lysis Coll Cardiol Collen compared complex coronary artery domain dose effect efficacy endothelial cells factor fibrin fibrin-specific fibrinogen fibrinolytic function gene Gurewich GUSTO GUSTO-I hemorrhage heparin hirudin HSKC increased infusion inhibition interaction intravenous Investigators kringle Kruithof Lijnen HR lysine lysis mg/kg minogen activator molecular mortality mutant outcome patency patients with acute peptide placebo plas plasma plasmin plasminogen activator inhibitor platelet pro-UK pro-urokinase protease protein pulmonary embolism randomized recanalization receptor recombinant regimen reocclusion reperfusion reteplase sc-uPA sequence single-chain staphylokinase streptokinase Study Group Thromb Haemost thrombin thrombolytic agents thrombolytic therapy thrombosis TIMI grade tion tissue plasminogen activator tissue-type plasminogen activator TNK-tPA Topol treatment trial uPAR urokinase urokinase-type plasminogen activator vascular venous vitro vivo